Julie Blatt

Julie Blatt

Auto-generated profile, based on publicly available information

Julie Blatt

Division of Hematology/Oncology Department of Pediatrics University of North Carolina Chapel Hill North Carolina USA

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 1999 in Medical and Pediatric Oncology
Verified
Journal Article
Closed access
PDF file
JBJulie Blatt
Julie Blatt

20 August 2010 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
JBJulie Blatt
Julie Blatt
JSJoseph Stavas
Joseph Stavas
BMBillie Moats‐Staats
Billie Moats‐Staats
JWJohn Woosley
John Woosley
DMDean S. Morrell
Dean S. Morrell

22 January 2019 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
KRKiersten W. Ricci
Kiersten W. Ricci
AHAdrienne M. Hammill
Adrienne M. Hammill
PMPaula Mobberley‐Schuman
Paula Mobberley‐Schuman
SNStephen C. Nelson
Stephen C. Nelson
JBJulie Blatt
Julie Blatt
DADenise M. Adams
Denise M. Adams

1 August 2003 in Journal of Pediatric Hematology/Oncology
Verified
Journal Article
Closed access
JBJulie Blatt
Julie Blatt
LLLinda Van Le
Linda Van Le
TWTimothy Weiner
Timothy Weiner
SSScott Sailer
Scott Sailer
Small cell carcinoma of the ovary is rare in adolescence. The etiology of such tumors is unknown. Several reports suggest that transgenerational exposure to diethylstilbestrol (DES) may have deleterious effects on the genitourinary tract. The authors describe a 15-year-old girl with small cell carcinoma of the ovary whose maternal grandmother had been taking DES while she was pregnant with the patient's mother. This case, while anecdotal, suggests that a transgenerational history of DES exposure should be noted, and that granddaughters with persistent abdominal pain even during childhood may need evaluation for genital tract abnormalities.

27 April 2011 in Clinical Pediatrics
Verified
Journal Article
Closed access
PDF file
JBJulie Blatt
Julie Blatt
DMDean S. Morrell
Dean S. Morrell
SBScott Buck
Scott Buck
CZCarlton Zdanski
Carlton Zdanski
SGStuart Gold
Stuart Gold
CBCraig N. Burkhart
Craig N. Burkhart
Propranolol has become first-line therapy for the treatment of infantile hemangiomas in many centers. Of 302 children with hemangiomas seen at the University of North Carolina from 2008 through 2010, 15.6% were treated with oral propranolol alone, 5.6% with topical timolol (a propranolol derivative) alone, and 2.3% with both. The use of these agents increased over time from 7% of patients seen in 2008 to 54% of patients first seen in 2010. Starting doses of propranolol ranged from 0.25 to 1 mg/kg/d, with target doses of 1 to 4 mg/kg/d. Serious side effects, noted in 6/54 (10.9%) patients, included somnolence, bradycardia, hypotension, hypoglycemia, and mottling of extremities.The authors confirm the variation in use of propranolol for vascular lesions and extend experience with timolol. They suggest daily home monitoring of patients for the first 2 weeks of initiating or increasing doses. Frequent feeding of infants and young children on this drug is recommended.

1 January 2013 in Drug Discovery Today
Verified
Journal Article
Closed access
JBJulie Blatt
Julie Blatt
SCSeth J. Corey
Seth J. Corey